New chemo cocktail aims to boost survival in elderly leukemia patients

NCT ID NCT06744556

Ongoing Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regimen leads to better event-free survival and remission rates. The study is active but not recruiting, with 41 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy drugs (homoharringtonine, daunorubicin, idarubicin, cytarabine, venetoclax, azacitidine)
What this could lead to: If successful, this could identify a more effective chemotherapy combination for elderly AML patients, potentially improving remission rates and survival.
What could go wrong: This is a small, early-phase trial (41 participants) with no results yet. The new regimen may not be better than existing options and could have serious side effects like infection or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML

Contacts and locations

Locations

Blood Diseases Hospital

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.